-
Prevention of CNS Progression in Diffuse Large B-cell Lymphoma_Craig Portell, MD; #IUCLS22
19:43
-
Recent Advances in the Frontline Treatment of DLBCL: Is There a New Standard of Care?_Laurie Sehn, MD, MPH; #IUCLS22
49:11
-
Module 4_Integrating Novel Approaches in Clinical Practice & Key Takeaways_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
19:16
-
Module 3_Emerging Approaches for Frontline Treatment_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
23:39
-
Module 2_Limitations of Traditional Therapies_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
10:50
-
Podium to Practice: Updates in the Treatment of DLBCL – From Chemotherapy to Novel Targeted Therapies_Justin Kline, MD_Laurie Sehn, MD
30:48
-
Future use of CD19 CAR T-cells beyond relapsed DLBCL_Jean Koff, MD, MS; #DDHO2021
3:22
-
Tumor Board #2: Relapsed/Refractory Diffuse Large B-Cell Lymphoma_Ranjana Advani, MD
19:58
-
Beyond the Congress Video Edits Susan O'Brien_recap_#BeyondASH21recap
3:44
-
Beyond the Congress Video Edits Nina Shah_recap_#BeyondASH21recap
4:20
-
Beyond the Congress Video Edits Kenneth Anderson_recap_#BeyondASH21recap
2:48
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company